Pembrolizumab and Palliative Radiotherapy in Lung
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
New Biomarkers for Invasive Fungal Infections in Paediatric Haemato-oncology
- Status
- TERMINATED
- Phase
- NA
Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Pembrolizumab in Combination With CRT for LA-SCCHN
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab in Untreated Extensive SCLC
- Status
- COMPLETED
- Phase
- PHASE2
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
- Status
- TERMINATED
- Phase
- PHASE3
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)
- Status
- COMPLETED
- Phase
- PHASE3
Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)
- Status
- COMPLETED
- Phase
- PHASE3
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
- Status
- TERMINATED
- Phase
- PHASE3
Safety and Tolerability Study of V501 in Japanese Boys (V501-200)
- Status
- COMPLETED
- Phase
- PHASE3
Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)
- Status
- TERMINATED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
- Status
- COMPLETED
- Phase
- PHASE3
Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
- Status
- COMPLETED
- Phase
- PHASE3
[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
- Status
- COMPLETED
- Phase
- PHASE1
Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
- Status
- COMPLETED
- Phase
- N/A
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3